» Articles » PMID: 23879965

MiR-487a Resensitizes Mitoxantrone (MX)-resistant Breast Cancer Cells (MCF-7/MX) to MX by Targeting Breast Cancer Resistance Protein (BCRP/ABCG2)

Overview
Journal Cancer Lett
Specialty Oncology
Date 2013 Jul 25
PMID 23879965
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer resistance protein (BCRP/ABCG2) specifically transports various chemotherapeutic agents and is involved in the development of multidrug resistance (MDR) in cancer cells. MicroRNAs (miRNAs) can play an important role in modulating the sensitivity of cancer cells to chemotherapeutic agents. Therefore, after confirming that BCRP was increased in the mitoxantrone (MX)-resistant MCF-7 breast cancer cell line MCF-7/MX compared with its parental sensitive MCF-7 cell line, we aimed to explore the miRNAs that regulate BCRP expression and sensitize breast cancer cells to chemotherapeutic agents. In the present study, bioinformatic analysis indicated that miR-487a was one of the miRNAs that could bind to the 3' untranslated region (3'UTR) of BCRP. Quantitative RT-PCR (qRT-PCR) analysis demonstrated that the expression of miR-487a was reduced in MCF-7/MX cells, and a luciferase reporter assay demonstrated that miR-487a directly bound to the 3'UTR of BCRP. Moreover, ectopic miR-487a down-regulated BCRP expression at the mRNA and protein levels, increasing the intracellular accumulation and cytotoxicity of MX in resistant MCF-7/MX breast cancer cells. Meanwhile, inhibition of miR-487a increased BCRP expression at the mRNA and protein levels and induced MX resistance in sensitive MCF-7 breast cancer cells. Furthermore, the reduced expression of BCRP and increased antitumor effects of MX were also detected in MCF-7/MX xenograft tumors treated with the miR-487a agmir. Thus, our results suggested that miR-487a can directly regulate BCRP expression and reverse chemotherapeutic drug resistance in a subset of breast cancers.

Citing Articles

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.


ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?.

Damiani D, Tiribelli M Biomedicines. 2024; 12(1).

PMID: 38255216 PMC: 10813371. DOI: 10.3390/biomedicines12010111.


Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?.

Bucci-Munoz M, Gola A, Rigalli J, Ceballos M, Ruiz M Life (Basel). 2023; 13(8).

PMID: 37629489 PMC: 10455762. DOI: 10.3390/life13081633.


Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.

Anand U, Dey A, Chandel A, Sanyal R, Mishra A, Pandey D Genes Dis. 2023; 10(4):1367-1401.

PMID: 37397557 PMC: 10310991. DOI: 10.1016/j.gendis.2022.02.007.


MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.

Gomes B, Rueff J, Rodrigues A Cancer Drug Resist. 2022; 2(3):618-633.

PMID: 35582590 PMC: 8992528. DOI: 10.20517/cdr.2019.55.